[Dabigatran, a new oral anticoagulant]

Area of Science:

• Pharmacology and Therapeutics
• Cardiovascular Medicine
• Clinical Trials

Context:

• Warfarin, a long-standing oral anticoagulant, has limitations hindering its clinical use.
• Dabigatran, a direct thrombin inhibitor, bypasses cytochrome P450 metabolism, eliminating the need for coagulation monitoring and dietary vitamin K restrictions.
• Drug interactions are also minimized with dabigatran therapy.

Purpose:

• To evaluate the non-inferiority of dabigatran compared to warfarin in preventing stroke and systemic embolism.
• To assess the safety profile of dabigatran, specifically major hemorrhage risk.
• To compare the incidence of hemorrhagic stroke between dabigatran and warfarin treatment groups.

Summary:

• The Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial involved 18,113 high-risk patients with non-valvular atrial fibrillation.
• Results indicated that dabigatran at 150 mg reduced stroke or systemic embolism compared to warfarin.
• Lower doses of dabigatran (110 mg) resulted in less major hemorrhage, and both doses reduced hemorrhagic stroke incidence.

Impact:

• Dabigatran is anticipated to be approved as a superior oral anticoagulant for stroke prevention in atrial fibrillation.
• The findings suggest dabigatran offers a safer and more effective alternative to warfarin.
• Ongoing trials are investigating Factor Xa inhibitors against warfarin for similar patient populations.